11,810 Shares in IQVIA Holdings Inc. $IQV Bought by Donoghue Forlines LLC

Donoghue Forlines LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,810 shares of the medical research company’s stock, valued at approximately $2,243,000.

A number of other hedge funds also recently bought and sold shares of the company. Verdence Capital Advisors LLC bought a new stake in IQVIA during the 2nd quarter valued at approximately $3,612,000. Amundi lifted its holdings in shares of IQVIA by 46.3% during the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after buying an additional 405,250 shares during the last quarter. Act Two Investors LLC acquired a new stake in shares of IQVIA in the second quarter worth $26,528,000. Diversified Trust Co boosted its holdings in IQVIA by 57.2% in the 3rd quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock valued at $8,087,000 after purchasing an additional 15,487 shares during the period. Finally, Oregon Public Employees Retirement Fund grew its position in IQVIA by 37.1% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 19,463 shares of the medical research company’s stock worth $3,697,000 after purchasing an additional 5,271 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on IQV shares. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Citigroup increased their price target on shares of IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a research note on Wednesday, October 29th. Stifel Nicolaus upped their price objective on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. BMO Capital Markets initiated coverage on IQVIA in a research note on Thursday, November 13th. They issued an “outperform” rating and a $260.00 target price for the company. Finally, JPMorgan Chase & Co. upped their price target on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $249.19.

IQVIA Stock Performance

IQV stock opened at $238.03 on Friday. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The firm has a market cap of $40.54 billion, a PE ratio of 32.65, a P/E/G ratio of 2.42 and a beta of 1.36. The business’s 50-day moving average price is $227.30 and its two-hundred day moving average price is $203.34.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same quarter last year, the firm posted $2.84 earnings per share. IQVIA’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.